InvestorsHub Logo
Followers 6
Posts 767
Boards Moderated 0
Alias Born 03/14/2015

Re: ddls post# 169731

Thursday, 01/24/2019 4:06:18 PM

Thursday, January 24, 2019 4:06:18 PM

Post# of 330276
At this point in time I have to agree with you. With the government on lockdown, what else can this company do, that it hasn't done for a decade, to generate sales and get the PPS moving toward a penny, instead of the triple zeros ? KN twitter has died. Sree is a PHd and this is his first place of employment since he graduated from Dr. McLeod's doctoral program at Binghamton. All he did was give a few talks and get his relative to run that bogus study out of Alabama. Maybe Allay is our last shot in the next few months for FDA menstrual clearance. That would sell. Woman we now know get better efficacy with Actipatch, as per the latest FDA rejection for back pain. How can they not clear Allay ? So, this it it. I think the end of the road for financial survival of Bioelectronics will be whether Allay is OTC or not. A R/S would be the final nail in the coffin, so that is out. WE NEED TO SELL SOMETHING...enough of the franks and beans.

I am off to Patchogue to buy some Actipatch. Going to see if Evocrazy is lying or not.